ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2308

Rheumatoid Arthritis Flares: Inflammatory Or Avalanche?

Caroline A. Flurey1, Marianne Morris2, Jon Pollock1, Rodney A. Hughes3, Pamela Richards4 and Sarah Hewlett5, 1Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom, 2University of the West of England, Bristol, United Kingdom, 3Rheumatology, St. Peters Hospital, Chertsey Surrey, United Kingdom, 4Academic Rheumatology Unit, University of Bristol, Bristol, United Kingdom, 5Academic Rheumatology, University of the West of England, Bristol, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Inflammation, pain, psychosocial factors and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: ARHP Rheumatoid Arthritis - Clinical Aspects: Clinical Practice/Patient Care

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Previous research has not addressed how RA patients’ symptoms change daily. The aim of this study was to explore symptom patterns during daily life and flare.

Methods: RA patients completed self-reported NRS (0-10) of pain, fatigue, swollen joints, stiffness, anger, frustration, worry and flare status (yes/no) daily for 3 months either on paper or online. This was an exploratory study and therefore not powered for statistical significance. Data were analysed for descriptive statistics and visually analysed with the use of graphs to identify symptom patterns.

Results: 28 patients took part: 5 withdrew, 6 had missing data for >10/91 days. The 17 patients included in the analysis were 15 female, mean age: 62.9yrs, disease duration: 18.6yrs, HAQ: 1.86
On plotting the symptoms onto graphs, 3 patients reported constant flare for 91 days (constant flare group), 6 patients self-reported ≥1 flare with periods of non-flare (intermittent flare group) and 8 patients did not report being in a flare (daily life group).
As expected, the group means of the individual symptoms were highest in the constant flare group and lowest in the daily life group. In the daily life group, patients’ individual mean pain scores ranged from 0.2 to 5.8, whereas in the intermittent flare group patients’ individual mean pain scores ranged from 2.5 to 7.0 and in the constant flare group patients’ individual mean pain scores ranged from 2.4 to 9.3. Thus some individual patients reported lower mean pain in flare than other patients reported on non-flare days, this was also the case with the other self-reported measures (see Table 1).
Further 5/6 patients in the intermittent flare group rated their symptoms as more severe on non-flare days than on days in flare. Thus patients may be using different criteria other than symptoms to decide whether they are in a flare.
Whilst many patients report traditional ‘Inflammatory Flare’ of symptoms, other patients may be reporting flare based on experiencing overall loss of control in their lives and thus defining their overall disease activity as more severe (in flare) despite individual symptoms being less severe. The term ‘Avalanche Flare’ is proposed for this cascading effect of life.

Conclusion: Definitions of flare vary within and between patients and may not be defined by symptom severity alone. Clinicians need to be aware that patients use ‘flare’ to explain a range of experiences. Understanding the terminology is necessary to improve communication and inform treatment decisions.

Table 1: Mean symptom scores for the three different trajectories 

 

 

Pain

Fatigue

Stiffness

Swollen Joints

Frustration

Anger

Worry

Constant
Flare
Group

Group Mean (SD)

4.3 (2.7)

4.7 (2.7)

3.6 (2.6)

3.9 (2.6)

3.7 (2.9)

3.1 (3.3)

3.7 (3.1)

Lowest Individual Patient Mean

2.4 (1.3)

4.4 (2.1)

2.3 (1.5

2.2 (1.4)

1.1 (1.3)

0.7 (0.9)

0.6 (0.9)

Highest Individual Patient Mean

9.3 (0.8)

9.3 (0.7)

9.5 (0.8)

9.5 (0.7)

9.0 (0.7)

8.9 (0.7)

8.9 (0.7)

Intermittent
Flare
Group

Group Mean

4.8 (2.3)

4.9 (2.0)

4.0 (2.1)

4.4 (2.1)

4.1 (2.2)

3.1 (2.6)

4.3 (2.4)

Lowest Individual Patient Mean

2.5 (1.2)

2.7 (1.2)

1.7 (0.7)

2.3 (0.8)

2.1 (0.7)

0.0 (0.1)

1.9 (0.8)

Highest Individual Patient Mean

7.0 (0.6)

7.4 (1.0)

6.2 (1.1)

6.5 (0.9)

6.3 (1.2)

5.7 (1.3)

7.8 (1.2)

Daily
Life
Group

Group Mean

3.1 (2.3)

3.6 (2.6)

2.4 (1.5)

2.7 (1.9)

2.8 (2.9)

2.2 (3.3)

2.7 (3.1)

Lowest Individual Patient Mean

0.2 (0.5)

0.4 (0.9)

0.3 (0.7)

0.5 (0.9)

0.0 (0.0)

0.0 (0.0)

0.0 (0.0)

Highest Individual Patient Mean

5.8 (2.2)

7.6 (2.0)

4.8 (1.6)

6.5 (1.6)

8.7 (0.7)

9.2 (0.7)

9.4 (0.6)

 


Disclosure:

C. A. Flurey,

Arthritis Research UK,

2;

M. Morris,
None;

J. Pollock,
None;

R. A. Hughes,
None;

P. Richards,
None;

S. Hewlett,

Arthritis Research UK,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-flares-inflammatory-or-avalanche/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology